ASRS 2021
Real-World & Clinical Trial Patients & Their Outcomes Differ
Oct 21, 2021
Most patients with neurovascular age-related macular degeneration (nAMD) would not qualify for the trials that inform currents standards of care, according to a study presented at the 39th Annual Scientific Meeting of ASRS 2021...
Read MoreOnly One-Third of Medicare Patients With nAMB Stay With Anti-VEGF Treatment
Oct 21, 2021
Only one-third of Medicare beneficiaries with neovascular age-related macular degeneration (nAMB) were “persistent” with anti-VEGF monotherapy treatment each year, according to a study presented at the 39th Annual Scientific...
Read MoreHigh Travel Burden Linked With Under-Representation in nAMD Trials
Oct 21, 2021
Geographic disparities in access to clinical trial sites exist for neovascular age-related macular degeneration (nAMD) in the United States, according to a study presented at the 38th Annual Scientific Meeting of the American...
Read MoreASRS: Medicare Survey Analysis Of Patients With Neovascular Age-Related Macular Degeneration
Oct 12, 2021
Only a third of Medicare beneficiaries were persistent with anti-VEGF monotherapy each year. Overall, two-thirds of patients treated with anti-VEGF at baseline (BL) reported similar or better visual function after 2 years....
Read MoreAdvertisement
Advertisement